EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
Laidlaw served as Co-Manager on the $129,000,000 Common Stock and Concurrent Private Placement for Soleno Therapeutics (SLNO)
Laidlaw is pleased to act as Co-Manager on Vikings 287.5mm dollar offering. Laidlaw Capital Markets was the Sole Book Runner on Viking’s 27.6mm dollar IPO in
On December 14, 2022, NLS Pharmaceutics (NASDAQ:NLSP,)(NASDAQ:NLSPW) announced the closing of its previously publicized purchase agreement with BVF Partners L.P. (“BVF”) comprised of an initial closing of
Laidlaw is pleased to have acted as the Sole Placement Agent on the $4,000,000 Private Placement for NLS Pharmaceutics. Read Article
Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option: Read Article
Perfect Moment is a luxury sportswear brand that has become known as an iconic staple in winter wear. The Perfect Moment collections marry the extreme
Laidlaw Capital Markets is pleased to have acted as Sole-Book Runner on the $3,500,000 Common Stock transaction for BioSig Technologies (BSGM). Read Article
Laidlaw Capital Markets is pleased to have acted as Underwriter on the $367,886,900 Cohen & Steers Real Estate Opportunities and Income Fund Offering alongside Bank
Laidlaw Capital Markets is pleased to have been Co-Lead Bookrunner on Cingulate Inc’s (CING) $25,000,000 Offering. Cingulate utilizes its proprietary Precision Timed Release (PTR) drug delivery
Laidlaw Capital Markets is pleased to be Financial Advisor on the MEI Pharma Inc’s $52,325,000 Follow-On Offering alongside Jefferies, Stifel, and Wells Fargo.” Link: https://www.meipharma.com/press-releases/mei-pharma-announces-closing-public-offering-common-stock-0
Laidlaw Capital Markets is pleased to be Financial Advisor on the EyePoint Pharmaceutical Inc’s $115,400,000 Follow-On Offering alongside Cowen and Guggenheim Securities
Laidlaw Capital Markets is pleased to have Co-Managed the $655,000,000 Guggenheim Active Allocation Trust offering alongside Bank of America, Morgan Stanley, & Wells Fargo.
Laidlaw Capital Markets is pleased to have Co-Managed the $2,040,000 Blackrock ESG Capital Allocation Trust offering alongside Bank of America, Morgan Stanley, UBS, & Wells
Laidlaw Capital Markets is pleased to have Lead Managed aTyr Pharma’s (LIFE) $86,250,000. Offering alongside Piper Sandler and RBC. Read Article: https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-pricing-75-million-public-offering-common
The Laidlaw Capital Markets team is pleased to announce our role as Sole Book-Runner and the pricing of a $10,000,000 Follow-on Offering for BioSig Technologies
Independent advisor platforms are attracting a growing number of international advisors to their networks. What is driving this growth and what are the benefits for
Laidlaw Wealth Management has hired an advisor from Wells Fargo’s international unit in Miami as the firm looks to expand its coverage of Latin America
Laidlaw Capital Markets is pleased to Co-Manage Aldeyra Therapeutics $125,000,000 financing alongside Jefferies and SVB Leerink. Over $300 million raised together since 2014, helping fuel
From globenewswire.com: Voltron Therapeutics, Inc. today announced positive data from its second set of preclinical animal testing of its HaloVax™ Self-Assembling Vaccine (SAV) against COVID-19.
The Team at Laidlaw Capital Markets is pleased to have acted as the Co-Manager on the $25,000,000 Follow-On Offering for iCAD, Inc. (ICAD). iCAD has
From globenewswire.com: Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the successful closing of a $4 million Series
The Team at Laidlaw Capital Markets is pleased to have acted as Financial Advisor on the $115,000,000 Follow-On Offering, alongside Guggenheim and Cowen. This is
From globenewswire.com: Voltron Therapeutics, Inc. today announced that it has appointed life science veteran Anthony Zook Executive Chairman of its Board of Directors. As a
Laidlaw Capital Markets is pleased to have Co-Managed Affimed’s $115,000,000 financing alongside Jefferies, SVB Leerink, and Credit Suisse. See full Press Release on Affimed Website
Laidlaw Capital Markets is pleased to have acted as the Sole Book-Runner on the $14,375,000 Follow-On Offering for Evoke Pharma (EVOK). Evoke has been a
Laidlaw Capital Markets is pleased to have served as a Financial Advisor to Delcath Systems on their $20,000,000 Follow-on Offering alongside Canaccord Genuity and Roth
Laidlaw Capital Markets is pleased to have served as a Lead Manager on a $147,500,000 Follow-On Offering for Curis Inc (CRIS). See press release
From prnewswire.com: Amesite Inc. (Nasdaq: AMST), an artificial intelligence software company providing online learning ecosystems for business, higher education, and K-12, announced today its CEO, Dr. Ann Marie
Laidlaw Wealth Management is pleased to announce its acquisition and partnership with Naples Wealth Planning a well-recognized and respected RIA based in Naples, Florida. The agreement will add four new offices in Naples, Tampa, Stuart, and Miami to Laidlaw’s existing Florida location in Boca Raton. In addition, this launches a new platform at Laidlaw to service and expand the 1099 model for advisors. This is an area Richard Calhoun, CEO of Laidlaw Wealth Management, knows well as he was instrumental in the growth of the Wells Fargo Advisors Financial Network from 245 offices to 642 offices, as Managing Director of Growth and Innovation…
Laidlaw acted as the Sole Book-Runner, and previously completed the companies Series A and B rounds over the last two years. See press release
Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the addition of Mr. Anthony (‘Tony’) Zook to its newly formed Investment and Operations Committee. As a global industry leader, Zook brings years of strategic experience to Laidlaw Venture Partners and is expected to be instrumental in the further development and evolution of the LVP portfolio of companies.
Laidlaw Capital Markets is pleased to have served as Financial Advisor to Arcturus Therapeutics on its $173,000,000 financing alongside Citigroup, Guggenheim Securities, and Barclays. Laidlaw
Ann Marie Sastry, founder and CEO of Amesite, joins “Squawk Box” to discuss how the Covid-19 pandemic is changing remote learnings for students and workers
Laidlaw Venture Partners, the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the addition of Jeff Conroy and George Serafin to its Board of Advisors. As industry leaders in Business Development and Regulatory/Compliance…
Laidlaw is pleased to have Co-Managed a $50,000,000 deal for Soleno Therapeutics (SLNO) with Guggenheim Partners. View Press Release
Laidlaw Venture Partners, the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the addition of Jeffrey O’Donnell and Dr. Ann Marie Sastry to its Board of Advisors. With more than 50 years of combined experience in leading companies across medical devices and artificial intelligence (AI) technology, O’Donnell and Sastry will help guide Laidlaw Venture Partners in building and expanding its already diverse portfolio of innovative companies.
Laidlaw Capital Markets is pleased to announce yesterday’s pricing of a $5,000,000 Follow-On Offering for Hoth Therapeutics (HOTH). Laidlaw proudly served as the Sole Book
Laidlaw Venture Partners client Biosig Technologies (BSGM) through its newly formed subsidiary ViralClear, closes $10,800,000 financing. Laidlaw is proud to have acted as am Introducing
Laidlaw Capital Markets is pleased to have acted as Co-Lead Manager on Delcath Systems’ (DCTH) $22,000,000 financing and uplisting to NASDAQ. Laidlaw proudly served as
Apart from the fact that 26mm Americans are filing for unemployment benefits, things are not that bad from a market perspective. Thanks to the massive and relatively rapid monetary and fiscal policy response, COVID has not taken the S&P 500 down as much as the 2008 Financial Crisis did. At this point in the 2008 experience (start the sequence with 9/29/08, the first -5% move for the S&P), the index was down -17.6%. Now, (start with 3/9/20, the first -5% “crash” day), the S&P 500 is actually up +3.3%. So, based on the valuation for U.S. large cap stocks, this indicates a market view that the worst outcomes are off the table.
Laidlaw Capital Markets is pleased to announce today’s pricing of a $70,000,000 Follow-On Offering for Arcturus Therapeutics (ARCT) around its Covid-19 vaccine and platform for
Podcast Series: A BRIGHTER FUTURE. Listen to our third session of the Laidlaw Five, our ongoing podcast series.
Podcast Series: A BRIGHTER FUTURE. Listen to our third session of the Laidlaw Five, our ongoing podcast series.
In the spirit of the Chinese curse, “may you live in interesting times,” we are certainly in the thick of it at the moment as efforts to contain the COVID-19 coronavirus to China have failed. There are now 140 countries that have reported infections and the weekend has seen the announcement of radical steps such as major U.S. cities (e.g. Chicago, IL; Los Angeles, CA; New York, NY) taking steps to sharply curtail public activities as the U.S. Centers for Disease Control & Prevention (CDC) has issued guidance that events involving 50 people or more not be held for the next two months…
Laidlaw & Company enhances their Wealth Management offering with Envestnet | MoneyGuide NEW YORK, NY, UNITED STATES, March 11, 2020 /EINPresswire.com/ — Laidlaw Wealth Management
Watch Ann Marie Sastry’s interview on CNBC’s “Squawk Alley”. The CEO of AMESITE talks about her company and how artificial intelligence can be used in
Laidlaw Capital Markets is pleased to announce today’s pricing of a $21,750,000 Follow-On Offering for EyePoint Pharmaceuticals (EYPT). Laidlaw proudly served as Co-Manager alongside Guggenheim,
Laidlaw Capital Markets is pleased to announce today’s pricing of a $10,000,000 Follow-On Offering for BioSig Technologies (BSGM). Laidlaw proudly served as the Sole Book
Laidlaw was proud to attend the closing bell ceremony at the NYSE yesterday. Defiance ETFs LLC is the first 5G ETF (NYSE Arca: FIVG) Alex Shtaynberger,
Laidlaw Capital Markets is pleased to announce today’s pricing of a $90,000,000 Follow-On Offering for Ziopharm Oncology (ZIOP). Laidlaw proudly served as Co-Manager alongside Jefferies,
Tech – Cloud Computing Growth Remains Solid, But Quality Control Issues Threaten Tech Majors: One of the major shifts of interest to investors has been that of enterprise computing to “cloud” platforms. In this regard, there have been three major competitors – AMZN, GOOGL & MSFT. While GOOGL results won’t be out until after the close Mon 10/28, the indications from AMZN (AWS 3Q19 revenues $9bn, +34.7% year/year vs. +37% y/y in 2Q19) and MSFT (Commercial Cloud 3Q19 revenues $11.6bn, +36% y/y) indicate that while cloud adoption growth is decelerating from earlier levels, it still remains quite solid. With major growth areas such as cloud computing remaining robust, the near-term prospects for the tech sector remain positive…
A BRIGHTER FUTURE Podcast Episode #1: “The Laidlaw Five” Welcome to “A Brighter Future”, our new Podcast Series. In this, our very first podcast, you’ll
Wealth management’s newest competitor is 177 years old Read the article below or see the original published article from OnWallStreet here An almost 177-year-old investment bank
Click here to see Dr. Ann Marie Sastry, chief executive officer, Amesite Inc, explain here disruptive online learning AI technology Also, see article below or
Tech – Cloud Computing Growth Remains Solid, But Quality Control Issues Threaten Tech Majors: One of the major shifts of interest to investors has been that of enterprise computing to “cloud” platforms. In this regard, there have been three major competitors – AMZN, GOOGL & MSFT. While GOOGL results won’t be out until after the close Mon 10/28, the indications from AMZN (AWS 3Q19 revenues $9bn, +34.7% year/year vs. +37% y/y in 2Q19) and MSFT (Commercial Cloud 3Q19 revenues $11.6bn, +36% y/y) indicate that while cloud adoption growth is decelerating from earlier levels, it still remains quite solid. With major growth areas such as cloud computing remaining robust, the near-term prospects for the tech sector remain positive…
The Laidlaw Capital Markets team is pleased to announce our role as a Financial Advisor to Beyond Air Inc (XAIR) on this mornings $11,500,000 Follow-On
Laidlaw Wealth Management Boosts Investment Offering With Green Harvest Deal December 12, 2019 12:21 PM Eastern Standard Time NEW YORK–(BUSINESS WIRE)–Laidlaw Wealth Management is pleased
Laidlaw Capital Markets is pleased to announce today’s pricing of Affimed (AFMD). Laidlaw served as Co-Manager, alongside Jefferies and SVB Leerink, for the $34,500,000 Follow-On
Laidlaw Capital Markets is pleased to serve as Financial Advisor to Molecular Templates (MTEM) on the pricing of its $50,000,000 Follow-On Offering. This is Laidlaw’s
Laidlaw Holdings LTD, the holding company for Laidlaw Wealth Management, Laidlaw Capital Markets and Laidlaw Private Equity, today announced that Richard J. Calhoun, Jr., the former Head of Innovation and Growth for Wells Fargo Advisors Financial Network (FiNet), has joined as the Chief Executive Officer of Laidlaw Wealth Management and the sixth member of the firm’s Board of Directors.
Laidlaw Capital Markets is pleased to announce today’s pricing of Soleno Therapeutics (SLNO). Laidlaw served as Co-Manager for the $15,400,000 Follow-On Offering. See full Press
Tech – Cloud Computing Growth Remains Solid, But Quality Control Issues Threaten Tech Majors: One of the major shifts of interest to investors has been that of enterprise computing to “cloud” platforms. In this regard, there have been three major competitors – AMZN, GOOGL & MSFT. While GOOGL results won’t be out until after the close Mon 10/28, the indications from AMZN (AWS 3Q19 revenues $9bn, +34.7% year/year vs. +37% y/y in 2Q19) and MSFT (Commercial Cloud 3Q19 revenues $11.6bn, +36% y/y) indicate that while cloud adoption growth is decelerating from earlier levels, it still remains quite solid. With major growth areas such as cloud computing remaining robust, the near-term prospects for the tech sector remain positive…
AdvisorHub’s CEO Tony Sirianni sits with established leaders of the largest firms, as well as up and coming disruptors. Here is his interview Ken Mathieson, Founding Partner of Laidlaw Wealth Management…
Laidlaw on a Recruiting Tear in 2019. Over Half a Billion Recruited in First Half of Year With Recent Addition of $250 Million, 35-Year Morgan Stanley Veteran
Watch David Garrity explain why Amazon may be at more antitrust risk than Facebook. David Garrity, chief market strategist from Laidlaw and Company U.K and
David Garrity Discusses the Impact of the Trade War with China Follow the links and read more below: 1) Bloomberg: https://www.bloomberg.com/news/audio/2019-05-28/we-are-in-a-technology-cold-war-laidlaw-s-garrity-radio 2) LinkedIn: https://www.linkedin.com/feed/update/urn:li:activity:6539488934144073729/ 3) Twitter: https://twitter.com/GVAResearch/status/1133724593385029632 1)
David Garrity on Big Tech Regulation Risk & Implications Follow the links and read more below: 1) Bloomberg: https://www.bloomberg.com/news/audio/2019-05-28/we-are-in-a-technology-cold-war-laidlaw-s-garrity-radio 2) LinkedIn: https://www.linkedin.com/feed/update/urn:li:activity:6539488934144073729/ 3) Twitter: https://twitter.com/GVAResearch/status/1133724593385029632 1) Tech – “Big